Diet in the Management of Acromegaly
Learn more about:
Related Access Program
Related Clinical Trial
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
Acromegaly: Balance, Falls and Fracture Risk
Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
Diet in the Management of Acromegaly
Hypoproteic Diet in Acromegaly
Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
Korean Regulatory Post Marketing Surveillance for Somavert
Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients
Vitamin D Metabolism in Patients With Endocrine Disorders
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
The TMS Treatment for Postoperative Headache in GH Tumor
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
Rhinological Outcomes in Endonasal Pituitary Surgery
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
Study in Polish Acromegalic Patients Treated With Somatuline Autogel
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The Observational Study of Growth Hormone-secreting Pituitary Tumors
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment
Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
Phase II Study With ITF2984 in Acromegalic Patients
Non Interventional Study For Patients Treated With Somavert®
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
Estrogen Treatment in Acromegalic Women
Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A.
ACRODAT Prospective Evaluation Study
Pegvisomant And Sandostatin LAR Combination Study
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
Tissue Biomarker for Pegvisomant Action
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
Predictive Factors Study
Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
Acromegaly – Before and After Treatment
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
Non Interventional Post Marketing Programme in Acromegaly
Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients
Cardiovascular Outcome After Surgery or Somatostatin Analogues
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
Long Term Study With B2036-PEG
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
Clomiphene Citrate for Treatment of Acromegaly
Cardiac (CMRI) Assessment of Acromegaly
Acromegaly Combination Treatment Study
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
Pasireotide LAR and Pegvisomant Study in Acromegaly
Somatuline Autogel: Acromegaly Self/Partner Injection Study
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
Effects of Sandostatin LAR® in Acromegaly
Open Label Study of Octreotide Implant in Patients With Acromegaly
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
Prospective Study on Changes in Acromegaly
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing’s Disease or Acromegaly
Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Rehabilitation Program in Patients With Acromegaly
Acute Application of Pegvisomant and Octreotide in Acromegaly
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
Prediction of Tumor Shrinkage in Acromegaly
Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients
Late Effects of Radiosurgery on Acromegaly Study
Ultrasound Guided Octreotide LAR Injection in Acromegaly
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Strict IGF-1 Control in Acromegaly
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
Fractionated Stereotactic Radiotherapy in Patients With Acromegaly
Validation Study of the SAGIT® Instrument in Acromegaly
Developing a Simple Recognition System of Acromegaly
Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance
Surgical Versus Medical Treatment of Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
Acromegaly & Sleep Apnoea
Lanreotide Levels in Acromegaly
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
Somatuline Predictive Factors in Acromegaly and NET
Acromegaly Treatment Quality of Life Study
Treatment Patterns and Treatment Outcomes for Acromegaly
Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Physiopathology of Sodium Retention in Acromegaly
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
Peri- and Post-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly During the First Year After Surgical Resection
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
Preoperative Octreotide Treatment of Acromegaly
The Treatment and Natural History of Acromegaly
Bone MicroArchitecture in Acromegaly
Reproducibility and Utility of OGTT in Acromegaly
A Prospective Study of Outcome After Therapy for Acromegaly
Epidemiology of Acromegaly in Denmark 1991-2010
Programme of Acromegaly Screening in Patients With Associated Somatic Disorders
Acromegaly: Patient And Physician Perspectives